Vantage logo

First blood: Rubius approaches its big test

The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…

Vantage logo

Bristol joins the pharma buyers club

An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.